Milestone Pharmaceuticals (NASDAQ:MIST) Earns Outperform Rating from Analysts at CIBC

CIBC started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report released on Tuesday, June 4th, FirstToMarketsRatingsTable reports. The firm issued an outperform rating and a $32.00 target price on the stock.

MIST has been the topic of a number of other research reports. Cowen initiated coverage on shares of Milestone Pharmaceuticals in a research note on Monday, June 3rd. They issued an outperform rating and a $32.00 price objective on the stock. Oppenheimer initiated coverage on shares of Milestone Pharmaceuticals in a research note on Tuesday, June 4th. They issued an outperform rating and a $32.00 price objective on the stock. Piper Jaffray Companies initiated coverage on shares of Milestone Pharmaceuticals in a research note on Monday, June 3rd. They issued an overweight rating and a $26.50 price objective on the stock. Finally, Jefferies Financial Group started coverage on shares of Milestone Pharmaceuticals in a research note on Monday, June 3rd. They issued a buy rating and a $28.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and an average price target of $30.10.

Shares of NASDAQ:MIST traded up $4.00 during midday trading on Tuesday, reaching $27.15. The company’s stock had a trading volume of 63,254 shares, compared to its average volume of 54,786. Milestone Pharmaceuticals has a twelve month low of $15.09 and a twelve month high of $27.95. The firm has a fifty day moving average price of $20.63.

In other news, major shareholder Holdings A/S Novo purchased 333,333 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Rtw Investments, Lp purchased 666,667 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $10,000,005.00. The disclosure for this purchase can be found here.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Further Reading: Are analyst ratings accurate?

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.